公开(公告)号：US10220064B2

公开(公告)日：2019-03-05

申请号：US15345842

申请日：2016-11-08

Applicant: Macau University of Science and Technology

Inventor： Hua Zhou ,  Quanbing Han ,  Yihan Zuo ,  Liang Liu ,  Ruiqi Yue

IPC: A61K36/258 ,  A61K31/715

Abstract: Methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition, particularly, but not exclusively ischemic heart disease and the subject is in particular a human, includes administering an effective amount of a carbohydrate composition extracted from Panax ginseng to the subject. The carbohydrate composition of the present invention extracted from Panax ginseng shows exceptional cardio-protective effect and, thus, provides a highly advantageous and highly promising treatment option for treatment of ischemic conditions and prevention of ischemia-reperfusion injury. The present invention further provides a method of protecting cells against hypoxia and reoxygenation induced cell death. Still further, the present invention provides a carbohydrate composition extracted from Panax ginseng and a pharmaceutical formulation comprising it.

公开(公告)号：US09955676B2

公开(公告)日：2018-05-01

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Ting Li ,  Kam Wai Wong ,  Zhihong Jiang ,  Hua Zhou

IPC: A01K67/027 ,  C12N15/00 ,  A61K49/00 ,  G01N33/573 ,  A61K31/70 ,  G01N33/574

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.

公开(公告)号：US10265298B2

公开(公告)日：2019-04-23

申请号：US15682564

申请日：2017-08-22

Applicant: Macau University of Science and Technology

Inventor： Ying Xie ,  Liang Liu ,  Hua Zhou

IPC: A61K31/357 ,  A61K31/352 ,  A61K9/20 ,  A61P1/16 ,  A61K9/00

Abstract: One example embodiment relates to a method of increasing bioavailability of silybin in a person. The method includes providing silybin and a flavonoid to the person, wherein the flavonoid is tangeretin or baicalein. Another example embodiment relates to a method of treating chronic liver disease in a person by administering silybin and a flavonoid to the person to treat the chronic liver disease.

公开(公告)号：US20190070170A1

公开(公告)日：2019-03-07

申请号：US15695304

申请日：2017-09-05

Applicant: Macau University of Science and Technology

Inventor： Hua Zhou ,  Jian-Xin Liu ,  Jin-Fang Luo ,  Chun-Song Chen ,  Elaine Lai-Han Leung ,  Liang Liu

IPC: A61K31/485 ,  G01N33/573 ,  C12Q1/68

Abstract: A method of selectively inhibiting the overexpression of mPGES-1 in a subject in need thereof includes a step of administering an effective amount of a selective mPGES-1 inhibitor or a salt thereof to the subject. A method of treating a subject suffering from a disease associated with an overexpression of mPGES-1 and having a risk of cardiovascular event includes the step of administering an effective amount of a selective mPGES-1 inhibitor to the subject.

公开(公告)号：US20180125906A1

公开(公告)日：2018-05-10

申请号：US15345842

申请日：2016-11-08

Applicant: Macau University of Science and Technology

Inventor： Hua Zhou ,  Quanbing Han ,  Yihan Zuo ,  Liang Liu ,  Ruiqi Yue

IPC: A61K36/258 ,  A61K31/715

CPC classification number: A61K36/258 ,  A61K31/715

Abstract: Methods of treating a subject suffering from an ischemic condition and of preventing an ischemia-reperfusion injury in a subject suffering from an ischemic condition, particularly, but not exclusively ischemic heart disease and the subject is in particular a human, includes administering an effective amount of a carbohydrate composition extracted from Panax ginseng to the subject. The carbohydrate composition of the present invention extracted from Panax ginseng shows exceptional cardio-protective effect and, thus, provides a highly advantageous and highly promising treatment option for treatment of ischemic conditions and prevention of ischemia-reperfusion injury. The present invention further provides a method of protecting cells against hypoxia and reoxygenation induced cell death. Still further, the present invention provides a carbohydrate composition extracted from Panax ginseng and a pharmaceutical formulation comprising it.

公开(公告)号：US09273088B2

公开(公告)日：2016-03-01

申请号：US14055883

申请日：2013-10-17

Applicant: Macau University of Science and Technology

Inventor： Jingrong Wang ,  Pei Luo ,  Hua Zhou ,  Wai In Chan ,  Liang Liu ,  Zhihong Jiang

IPC: A61K31/704 ,  C07J17/00

CPC classification number: C07J17/005 ,  A61K31/704

Abstract: The present invention provides novel ginsenoside derivative compounds and the use thereof in protection against ischemia/reperfusion injury.

Abstract translation: 本发明提供新型人参皂苷衍生物化合物及其在防止缺血/再灌注损伤中的应用。

公开(公告)号：US20180289666A1

公开(公告)日：2018-10-11

申请号：US15481720

申请日：2017-04-07

Applicant: Macau University of Science and Technology

Inventor： Ying Xie ,  Liang Liu ,  Hua Zhou ,  Zhong-Wen Yuan ,  Yan-Fang Zheng ,  Sen-Ling Feng ,  Xiao-Hui Zeng ,  Hui Wang

IPC: A61K31/366

Abstract: A method for reducing abnormalities in lipid metabolism and for reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism includes administering an effective amount of a flavonolignan to the subject. The subject may additionally suffer from a liver disease, obesity, hypertension, diabetes mellitus or a metabolic syndrome. Further provided is a method for reducing the risk of a cardiovascular disease in a subject suffering from an autoimmune inflammatory disease accompanied by abnormalities in lipid metabolism and a method for reducing hepatic abnormalities and reducing inflammation in a subject suffering from an autoimmune inflammatory disease accompanied by hepatic abnormalities. Still further provided is a method for reducing liver damages associated with the treatment of rheumatoid arthritis with a disease-modifying antirheumatic drug or a non-steroidal anti-inflammatory drug.

公开(公告)号：US09051348B2

公开(公告)日：2015-06-09

申请号：US14040738

申请日：2013-09-30

Applicant: Macau University of Science and Technology

Inventor： Liang Liu ,  Liping Bai ,  Hang Dong ,  Kam Wai Wong ,  Zhihong Jiang ,  Hua Zhou

IPC: C07J17/00

CPC classification number: C07J17/005

Abstract: The present invention relates to a novel compound derived from ginsenoside Rh2, the preparation methods and the use thereof in treating cancers.

Abstract translation: 本发明涉及一种衍生自人参皂苷Rh2的新型化合物，其制备方法及其在治疗癌症中的应用。